{"id":38848,"date":"2025-04-11T12:07:58","date_gmt":"2025-04-11T06:37:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=38848"},"modified":"2025-04-11T12:07:58","modified_gmt":"2025-04-11T06:37:58","slug":"biocon-share-price-up-fda-approval-bevacizumab","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/biocon-share-price-up-fda-approval-bevacizumab\/","title":{"rendered":"Biocon Share Price in Focus Today: Biocon Gets FDA Approval for Bevacizumab Biosimilar"},"content":{"rendered":"<p><a href=\"https:\/\/univest.in\/stocks\/biocon\/biocon-ltd-share-price-today\">Biocon Share Price<\/a> is up by 3.41% or \u20b910.30, reaching \u20b9316.60 today on 11th April 2025. Based on the recent news updates, investors gained high confidence in Biocon shares for the near and long term.&nbsp;<\/p><p><a href=\"https:\/\/univest.in\/share-market-today\"><strong><em>Share Market Today<\/em><\/strong><\/a><strong><em>, Stocks in news<\/em><\/strong>: Biocon Biologics Limited, a subsidiary of Biocon Limited, has received an FDA approval for Jobevne (Bevacizumab Biosimilar) for cancer therapy. The approval was obtained on 10th April 2025, marking the company\u2019s 7th approval in the United States. It strengthens Biocon Limited&#8217;s leadership in affordable oncology solutions.&nbsp;<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-up-fda-approval-bevacizumab\/#Strong_Clinical_Evidence_for_FDA_Approval\" title=\"Strong Clinical Evidence for FDA Approval\">Strong Clinical Evidence for FDA Approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-up-fda-approval-bevacizumab\/#What_Biocons_CEO_Says\" title=\"What Biocon\u2019s CEO Says?\">What Biocon\u2019s CEO Says?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-up-fda-approval-bevacizumab\/#Biocon_Biologics_Leading_Biosimilar_Innovation\" title=\"Biocon Biologics: Leading Biosimilar Innovation\">Biocon Biologics: Leading Biosimilar Innovation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-up-fda-approval-bevacizumab\/#Summary\" title=\"Summary\">Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-up-fda-approval-bevacizumab\/#Explore_Other_News_Articles\" title=\"Explore Other News Articles\">Explore Other News Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Strong_Clinical_Evidence_for_FDA_Approval\"><\/span><strong>Strong Clinical Evidence for FDA Approval<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Here are the elements that influenced the FDA\u2019s decision to approve Biocon\u2019s Bevacizumab Biosimilar:<\/p><ul class=\"wp-block-list\"><li>Pharmacokinetics<\/li>\n\n<li>Immunogenicity<\/li>\n\n<li>Nonclinical and Functional Data<\/li>\n\n<li>Safety and Efficacy<\/li>\n\n<li>Structural and Analytical Similarity<\/li><\/ul><p>FDA\u2019s approval confirmed no clinically meaningful differences between Jobevne and Avastin. It met the high standards required for biosimilar approval in the United States.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Biocons_CEO_Says\"><\/span><strong>What Biocon\u2019s CEO Says?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><em>\u201cThis marks our <\/em><strong><em>third U.S. FDA approval for an oncology biosimilar<\/em><\/strong><em> and the <\/em><strong><em>seventh overall<\/em><\/strong><em>. It significantly strengthens our oncology portfolio and reiterates our commitment to providing affordable access to life-saving biologics in the U.S. and globally,\u201d<\/em> ~ Shreehas Tambe (CEO &amp; Managing Director of <a href=\"https:\/\/www.bioconbiologics.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Biocon Biologics<\/a>).<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biocon_Biologics_Leading_Biosimilar_Innovation\"><\/span><strong>Biocon Biologics: Leading Biosimilar Innovation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Biocon operates in 120+ countries and acts as a global trailblazer in biosimilar and insulin manufacturing. Its end-to-end capabilities, from research development to commercialisation, make it one of the few companies worldwide capable of delivering lab-to-market biosimilar innovation at scale. The global infrastructure of Biocon includes:<\/p><ul class=\"wp-block-list\"><li>R&amp;D Centers<\/li>\n\n<li>Strategic Alliances<\/li>\n\n<li>State-of-the-Art Manufacturing Units<\/li><\/ul><p>Biocon Biologics Limited is strategically positioned to emerge as a dominant force in the US Biosimilar market, which is projected to reach $40 billion by 2030.&nbsp;<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary\"><\/span><strong>Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The FDA approval of Jobevne is a major achievement for both Biocon Biologics and the global healthcare community. With biosimilars playing an increasingly vital role in reducing healthcare expenses, Biocon&#8217;s expanding presence in critical therapeutic segments such as cancer ensures that patients across the United States and the globe have greater access to life-saving therapies.<\/p><p>Biocon Biologics&#8217; latest achievement brings fresh confidence to the future of biosimilar drugs, which are low-cost, effective, and available.<\/p><p><strong>For live stocks updates, dividend alerts, and expert verdicts, stay informed with Univest!<\/strong><\/p><p><strong><em>Disclaimer<\/em><\/strong><em>: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.&nbsp;<\/em><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Explore_Other_News_Articles\"><\/span><strong>Explore Other News Articles<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/sensex-jumps-1100-nifty-hits-22800\">Stock Market Today: Sensex Jumps 1,100 Pts: Nifty Scales 22,800 as Gains Extend; Check Details<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/stocks-to-watch-today-11th-april-2025\">Stocks to Watch Today: 11th April 2025 | Sun Pharma, RITES, BHEL, TATA MOTORS, NBCC, SRF &amp; More!<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-2025-earnings-miss-estimates\">TCS Q4 Results Miss Estimates: Net Profit Down 2% YoY | \u20b930 Dividend Declared<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/tata-capital-confidential-ipo-drhp-2025\">Tata Capital Files \u20b915,000 Crore IPO via Confidential DRHP | Check All Details Here<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/boat-ipo-confidential-filing-details\">BoAt\u2019s Imagine Marketing Filed \u20b92,000 Crore IPO via Confidential Route | Check All Details Here<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/is-stock-market-closed-tomorrow\">Is the Indian Stock Market Closed Tomorrow on Mahavir Jayanti 2025? Check Details Here<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/suzlon-falls-3-percent-selloff-pressure\">Suzlon Share Price Falls 3.05% Amid Order Cancellations and Selloffs<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zomato-share-rises-coo-exit\">Zomato Rebrands to Eternal Limited: Stock Opened Higher at \u20b9216 Amid COO Exit<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Biocon Share Price is up by 3.41% or \u20b910.30, reaching \u20b9316.60 today on 11th April 2025. Based on the recent news updates, investors gained high confidence in Biocon shares for the near and long term.&nbsp; Share Market Today, Stocks in news: Biocon Biologics Limited, a subsidiary of Biocon Limited, has received an FDA approval for<\/p>\n","protected":false},"author":23,"featured_media":38849,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[1244,1245],"class_list":["post-38848","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-biocon","tag-biocon-share-price"],"metadata":{"_edit_lock":["1744357794:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_seo_score":["16"],"rank_math_internal_links_processed":["1"],"_thumbnail_id":["38849"],"rank_math_primary_category":["842"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"_wp_page_template":["default"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_canonical_url":["https:\/\/univest.in\/blogs\/biocon-share-price-up-fda-approval-bevacizumab"],"rs_page_bg_color":[""],"rank_math_title":["Biocon Share Price 3% Up Amid FDA Approval for Bevacizumab Biosimilar"],"rank_math_description":["Biocon Share Price jumps 3.41% in strong pharma rally. Biocon's price surge is wholly attributable to FDA approval for Bevacizumab Biosimilar in the US. Know more."],"rank_math_analytic_object_id":["1785"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2025\/04\/11115207\/biocon-3.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/38848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=38848"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/38848\/revisions"}],"predecessor-version":[{"id":38851,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/38848\/revisions\/38851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/38849"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=38848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=38848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=38848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}